Boston Partners bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 69,083 shares of the company's stock, valued at approximately $915,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Pathstone Holdings LLC grew its holdings in Takeda Pharmaceutical by 1.0% during the third quarter. Pathstone Holdings LLC now owns 430,676 shares of the company's stock valued at $6,124,000 after purchasing an additional 4,280 shares during the period. Caprock Group LLC raised its holdings in shares of Takeda Pharmaceutical by 7.7% during the third quarter. Caprock Group LLC now owns 34,304 shares of the company's stock worth $488,000 after acquiring an additional 2,454 shares during the period. Advisors Asset Management Inc. lifted its position in Takeda Pharmaceutical by 41.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 51,226 shares of the company's stock valued at $728,000 after acquiring an additional 14,992 shares in the last quarter. Smithfield Trust Co boosted its position in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock worth $49,000 after buying an additional 1,490 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Takeda Pharmaceutical by 17.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 187,165 shares of the company's stock worth $2,661,000 after acquiring an additional 27,628 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.
Takeda Pharmaceutical Stock Down 0.3 %
Takeda Pharmaceutical stock traded down $0.05 during mid-day trading on Wednesday, reaching $15.00. The company's stock had a trading volume of 1,578,187 shares, compared to its average volume of 1,794,727. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.31. The company has a market capitalization of $47.71 billion, a price-to-earnings ratio of 37.49, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The business's 50 day simple moving average is $14.04 and its 200 day simple moving average is $13.91.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.
Takeda Pharmaceutical Company Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
